The grades of 6 Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Questcor Pharmaceuticals (NASDAQ:QCOR) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Questcor Pharmaceuticals develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Revisions, Equity, Margin Growth, and Sales Growth, QCOR also gets A’s. The stock price has risen 17.4% over the past month, better than the 3.7% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of QCOR stock.
Nektar Therapeutics (NASDAQ:NKTR) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. For more information, get Portfolio Grader’s complete analysis of NKTR stock.
This week, Optimer Pharmaceuticals‘s (NASDAQ:OPTR) ratings are up from a B last week to an A. Optimer Pharmaceuticals discovers, develops, and commercializes anti infective products. Shares of OPTR have risen 10.4% over the past month. For more information, get Portfolio Grader’s complete analysis of OPTR stock.
SciClone Pharmaceuticals (NASDAQ:SCLN) earns a B this week, jumping up from last week’s grade of C. SciClone Pharmaceuticals is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. The stock’s trailing PE Ratio is 6.9. For more information, get Portfolio Grader’s complete analysis of SCLN stock.
Acura Pharmaceuticals‘s (NASDAQ:ACUR) ratings are looking better this week, moving up to a B from last week’s C. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
This is a strong week for Repros Therapeutics (NASDAQ:RPRX). The company’s rating climbs to A from the previous week’s B. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. Wall Street seems to agree with the upgrade and has propelled the stock up 38.6% over the past month. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.